Actively Recruiting
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Led by Medical University of Vienna · Updated on 2024-11-25
290
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
CONDITIONS
Official Title
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 50 years or older
- Active neovascular age-related macular degeneration confirmed by imaging
- Best corrected visual acuity of 0.1 (20/200) or better in the study eye
- No significant scarring or geographic atrophy affecting the central vision area
- Ability and willingness to attend study visits and follow procedures
- Signed informed consent form
You will not qualify if you...
- Allergy to fluorescein, ranibizumab, aflibercept, brolucizumab, or related ingredients
- Eye surgery in the study eye within 3 months before the study
- History of pseudophakic cystoid macular edema
- Eye surgeries like glaucoma filtration, corneal transplant, or cataract extraction within 6 months or complications within 12 months before the study
- Uncontrolled glaucoma or very high optic nerve damage in the study eye
- Absence of the natural lens in the study eye
- Retinal pigment epithelial tear involving the macula in the study eye
- Other eye conditions likely needing treatment or surgery during the study
- Active inflammation or infection in or around the study eye
- History of vitreous hemorrhage, retinal detachment, or macular hole in the study eye
- Current abnormal blood vessel growth or bleeding in the eye
- Active eye surface infections like blepharitis, keratitis, scleritis, or conjunctivitis
- Eye conditions that could affect treatment response or study participation
- Corneal damage affecting vision in the study eye
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Ophthalmology, Medical University of Vienna, Austria
Vienna, State of Vienna, Austria, 1090
Actively Recruiting
Research Team
S
Stefan Sacu, MD
CONTACT
U
Ursula Schmidt-Erfurth, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here